Rowlandmiller & PARTNERS.ADV Lowers Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Rowlandmiller & PARTNERS.ADV reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,933 shares of the biopharmaceutical company’s stock after selling 609 shares during the period. Rowlandmiller & PARTNERS.ADV’s holdings in Gilead Sciences were worth $2,845,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in GILD. Hennessy Advisors Inc. lifted its holdings in Gilead Sciences by 0.7% in the 1st quarter. Hennessy Advisors Inc. now owns 61,100 shares of the biopharmaceutical company’s stock worth $4,476,000 after purchasing an additional 400 shares in the last quarter. Fifth Third Wealth Advisors LLC raised its holdings in shares of Gilead Sciences by 60.0% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 7,851 shares of the biopharmaceutical company’s stock worth $575,000 after acquiring an additional 2,945 shares in the last quarter. Register Financial Advisors LLC raised its holdings in shares of Gilead Sciences by 6.4% during the 1st quarter. Register Financial Advisors LLC now owns 4,166 shares of the biopharmaceutical company’s stock worth $305,000 after acquiring an additional 250 shares in the last quarter. Kathmere Capital Management LLC raised its holdings in shares of Gilead Sciences by 18.4% during the 1st quarter. Kathmere Capital Management LLC now owns 2,964 shares of the biopharmaceutical company’s stock worth $217,000 after acquiring an additional 460 shares in the last quarter. Finally, Financial Management Professionals Inc. raised its holdings in shares of Gilead Sciences by 6.5% during the 1st quarter. Financial Management Professionals Inc. now owns 5,878 shares of the biopharmaceutical company’s stock worth $431,000 after acquiring an additional 361 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the sale, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at $8,398,843.87. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,847 shares of company stock valued at $3,033,340. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Up 1.8 %

Shares of GILD opened at $88.78 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.95 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $89.21. The stock’s 50 day moving average is $81.87 and its two-hundred day moving average is $73.17. The firm has a market cap of $110.61 billion, a P/E ratio of 246.61, a PEG ratio of 2.98 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The business had revenue of $6.95 billion for the quarter, compared to the consensus estimate of $6.64 billion. Analysts predict that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were paid a $0.77 dividend. The ex-dividend date of this dividend was Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.47%. Gilead Sciences’s payout ratio is presently 855.56%.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on GILD. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Thursday, August 15th. Barclays increased their price target on Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $74.00 to $96.00 in a research report on Monday. Wells Fargo & Company upgraded Gilead Sciences from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $78.00 to $100.00 in a research note on Monday, October 7th. Finally, Royal Bank of Canada upped their price objective on Gilead Sciences from $74.00 to $75.00 and gave the stock a “sector perform” rating in a research note on Friday, October 4th. Ten equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $86.85.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.